<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-100318" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Amantadine Keratopathy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Moshirfar</surname>
            <given-names>Majid</given-names>
          </name>
          <aff>University of Utah/John Moran Eye Center; Hoopes Vision/HDR Research Center; Utah Lions Eye Bank</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Baker</surname>
            <given-names>Preston</given-names>
          </name>
          <aff>McGovern Medical School</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ronquillo</surname>
            <given-names>Yasmyne</given-names>
          </name>
          <aff>Hoopes Vision Research Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Majid Moshirfar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preston Baker declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Yasmyne Ronquillo declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>18</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-100318.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Amantadine keratopathy is a rare dose-dependent disease process in which the drug amantadine causes damage to corneal endothelial cells through unknown mechanisms. Damage to the endothelium can ultimately lead to severe corneal edema with decreased visual acuity. Edema is typically reversible with discontinuation of the drug, but irreversible cases requiring corneal transplants have been reported. This activity describes the evaluation and management of amantadine keratopathy and highlights the role of the interprofessional team in improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the pathophysiology of amantadine keratopathy.</p></list-item><list-item><p>Explain the risk factors for developing amantadine keratopathy.</p></list-item><list-item><p>Identify the treatment options available for amantadine keratopathy.</p></list-item><list-item><p>Describe the importance of collaboration and communication among the interprofessional team to advance the care of amantadine keratopathy and to improve outcomes for patients with this condition.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=100318&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=100318">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-100318.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Amantadine was originally discovered as an anti-viral to treat influenza in the 1950s. In the late 1960s, it was discovered to be useful in treating tremors and dyskinesia associated with Parkinson's disease and began to be widely used for this purpose. Today amantadine is prescribed for some chronic neurodegenerative and neurocognitive diseases. The mechanism of action of amantadine is largely unknown. Amantadine keratopathy is a term used to describe corneal edema and subsequent decrease in visual acuity that is assumed to be caused by the drug. Corneal edema typically resolves with discontinuation of the drug, although cases requiring corneal transplants have been reported.</p>
      </sec>
      <sec id="article-100318.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The acute onset of corneal edema with amantadine treatment and the resolution with discontinuation of the drug shows a causal relationship.<xref ref-type="bibr" rid="article-100318.r1">[1]</xref><xref ref-type="bibr" rid="article-100318.r2">[2]</xref><xref ref-type="bibr" rid="article-100318.r3">[3]</xref><xref ref-type="bibr" rid="article-100318.r4">[4]</xref>&#x000a0;Studies show that amantadine keratopathy occurs in a cumulative and dose-dependent manner.<xref ref-type="bibr" rid="article-100318.r5">[5]</xref><xref ref-type="bibr" rid="article-100318.r6">[6]</xref>&#x000a0;There is a negative correlation between the duration of treatment and endothelial cell density (ECD).<xref ref-type="bibr" rid="article-100318.r1">[1]</xref>&#x000a0;The greatest relative risk of corneal edema is seen in patients who are given a high dose for a short period (2000 mg within 30 days RR=2.38).<xref ref-type="bibr" rid="article-100318.r6">[6]</xref>&#x000a0;A 4000 mg cumulative dose prescribed within 30 days led to a 3-fold increased risk in corneal edema.<xref ref-type="bibr" rid="article-100318.r6">[6]</xref>&#x000a0;Amantadine could act synergistically with other medications that are toxic to the cornea, increasing the risk for corneal edema and permanent damage in these patients.<xref ref-type="bibr" rid="article-100318.r2">[2]</xref><xref ref-type="bibr" rid="article-100318.r7">[7]</xref></p>
        <p>Although ECD is not a highly reliable marker of clinical outcomes, patients with decreased baseline ECD may be at increased risk of amantadine keratopathy. ECD decreases linearly throughout one's lifetime, and the standard deviation of ECD increases in later decades of life.<xref ref-type="bibr" rid="article-100318.r8">[8]</xref><xref ref-type="bibr" rid="article-100318.r9">[9]</xref>&#x000a0;A study of corneas from a large cornea donor database showed that prevalence of ECD &#x0003c;2000 was substantially increased in the eyes of patients &#x0003e;75 years old (odds ratio (OR)=24.6), eyes 65-74 years old (OR=17.8), and eyes with a previous history of cataract surgery (OR=4.8).<xref ref-type="bibr" rid="article-100318.r9">[9]</xref></p>
      </sec>
      <sec id="article-100318.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The incidence and prevalence of amantadine keratopathy in the general population are not known as the majority of studies exclude patients with ocular comorbidities (e.g., glaucoma, prior history of corneal edema) where amantadine keratopathy may have an increased prevalence. Amantadine keratopathy has an equal preponderance in males and females.<xref ref-type="bibr" rid="article-100318.r6">[6]</xref><xref ref-type="bibr" rid="article-100318.r10">[10]</xref>&#x000a0;In a phase IV post-marketing surveillance study, the 2-year relative risk (RR) of developing corneal edema or Fuchs dystrophy in patients prescribed amantadine is 1.79 when compared to the general population. Over this period, 36 (0.27%) of the 13,137 patients receiving amantadine (99% of whom received a prescription of 100 mg BID) were diagnosed with Fuchs dystrophy or corneal edema.<xref ref-type="bibr" rid="article-100318.r10">[10]</xref>&#x000a0;</p>
        <p>There is an increased incidence of amantadine keratopathy within months of treatment initiation, but cases have been reported as late as 6 years after starting therapy, so the relative risk is likely greater than this.<xref ref-type="bibr" rid="article-100318.r6">[6]</xref><xref ref-type="bibr" rid="article-100318.r10">[10]</xref><xref ref-type="bibr" rid="article-100318.r11">[11]</xref>&#x000a0;The largest retrospective cohort study conducted on amantadine keratopathy showed that patients prescribed amantadine for Parkinson's disease specifically have an increased risk of developing amantadine keratopathy when compared to individuals taking amantadine for other reasons (RR=1.97).<xref ref-type="bibr" rid="article-100318.r6">[6]</xref>&#x000a0;This increased risk is likely due to long term treatment. The same study calculates a RR of 1.97 over a 15-year period for Parkinson's patients on amantadine when compared to healthy controls not taking amantadine.<xref ref-type="bibr" rid="article-100318.r6">[6]</xref></p>
      </sec>
      <sec id="article-100318.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Amantadine causes permanent damage to the corneal endothelium and a decrease in corneal endothelial cell density by unknown mechanisms.<xref ref-type="bibr" rid="article-100318.r4">[4]</xref><xref ref-type="bibr" rid="article-100318.r11">[11]</xref><xref ref-type="bibr" rid="article-100318.r12">[12]</xref>&#x000a0;Bovine cornea cell cultures showed no signs of corneal endothelial cell apoptosis, although the duration of incubation may not have been sufficient to induce such a change.<xref ref-type="bibr" rid="article-100318.r13">[13]</xref>&#x000a0;Corneal endothelial cells are located in a monolayer posterior to Descemet's membrane and the stroma. These cells function to dehydrate and thus maintain the clarity of the cornea via sodium-potassium adenosine triphosphatase (Na/K&#x000a0;ATPase) pumps. Loss of corneal endothelium led to edema and blurred vision at a cell density of about 500 cells/mm. Corneal edema in amantadine keratopathy frequently causes loss of visual acuity to 20/200 or hand motion.<xref ref-type="bibr" rid="article-100318.r2">[2]</xref><xref ref-type="bibr" rid="article-100318.r3">[3]</xref><xref ref-type="bibr" rid="article-100318.r4">[4]</xref><xref ref-type="bibr" rid="article-100318.r11">[11]</xref><xref ref-type="bibr" rid="article-100318.r12">[12]</xref>&#x000a0;</p>
        <p>Because damage to the corneal endothelium is permanent, edema may persist even after discontinuation of the drug, and a corneal transplant may be&#x000a0;necessary to restore vision.<xref ref-type="bibr" rid="article-100318.r12">[12]</xref>&#x000a0;The primary action of amantadine as a neurologic drug is through an indirect increase in extracellular dopamine by non-competitive inhibition of NMDA receptors. Recent case reports of corneal edema with a similar clinical picture have been attributed to memantine, a drug with similar structure and mechanism of action.<xref ref-type="bibr" rid="article-100318.r14">[14]</xref>&#x000a0;Amantadine also has several off-target effects that may contribute to corneal edema.<xref ref-type="bibr" rid="article-100318.r13">[13]</xref><xref ref-type="bibr" rid="article-100318.r15">[15]</xref>&#x000a0;In a study on bovine cornea cultures, amantadine was shown to inhibit K channels similar to the effect of the K channel blocker clotrimazole. Cells in cultures showed an increase in area and cell volume consistent with edema, and gap junctions between cells were disrupted.<xref ref-type="bibr" rid="article-100318.r13">[13]</xref>&#x000a0;</p>
        <p>Another recent case study showed that the dopaminergic agonists ropinirole, methylphenidate, and resiniferatoxin induced corneal edema with a similar clinical presentation to amantadine keratopathy.<xref ref-type="bibr" rid="article-100318.r15">[15]</xref>&#x000a0;Dopamine D1 receptors (DRD1) have been found on corneal endothelial cells, and dopamine sensitivity has been linked to decreased corneal transparency. Based on these studies, it is likely that acute corneal edema in amantadine keratopathy occurs secondary to interactions with multiple corneal endothelial cell receptors that ultimately disrupt intracellular fluid osmolarity and corneal endothelial cell organization. Damage to the endothelium has been measured by different parameters, including a decrease in endothelial cell density (ECD), a decrease in cell hexagonality (CH), and an increase in the coefficient of variation (CoV).<xref ref-type="bibr" rid="article-100318.r1">[1]</xref><xref ref-type="bibr" rid="article-100318.r4">[4]</xref><xref ref-type="bibr" rid="article-100318.r5">[5]</xref>&#x000a0;</p>
        <p>Endothelial cell size variation (CoV) demonstrates that some endothelial cells are enlarging to fill gaps and compensate for the loss of surrounding endothelial cells. The percentage of hexagonal cells decreases in response to chemical, mechanical, or hypoxic stress. These parameters are frequently used as markers of endothelial cell viability and pre-operative risk in patients with intrinsic disease of corneal endothelium such as Fuchs endothelial corneal dystrophy (FECD). Corneal endothelium damage may be present in eyes without corneal edema or decreased visual acuity in patients on amantadine therapy.<xref ref-type="bibr" rid="article-100318.r1">[1]</xref><xref ref-type="bibr" rid="article-100318.r5">[5]</xref>&#x000a0;Regardless of whether or not keratopathy develops, endothelial cells do not regenerate after amantadine toxicity occurs.<xref ref-type="bibr" rid="article-100318.r4">[4]</xref><xref ref-type="bibr" rid="article-100318.r5">[5]</xref><xref ref-type="bibr" rid="article-100318.r11">[11]</xref>&#x000a0;It is likely that amantadine keratopathy occurs in a dose-dependent fashion, with significant variation among individuals in the concentration of amantadine that is ultimately present in the aqueous, even when the prescribed dose of amantadine is the same.<xref ref-type="bibr" rid="article-100318.r4">[4]</xref><xref ref-type="bibr" rid="article-100318.r6">[6]</xref></p>
      </sec>
      <sec id="article-100318.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>In almost all case reports of amantadine keratopathy, the patient describes a sudden onset of painless, bilateral blurring of vision with progressive worsening in the following months. Many patients have a visual acuity of 20/200 or worse at the time of presentation to an ophthalmologist. This history in patients with no past ocular disease, and negative family history of ocular disease, should prompt an extensive workup of medical history and medication exposure. If a patient is taking amantadine, the duration and dosage of treatment should be determined to stratify the patient's risk of amantadine keratopathy. It is important to consider undiagnosed ocular pathologies that may be contributing to visual loss, as amantadine keratopathy is a very rare diagnosis with a nonspecific presentation.</p>
        <p>In a patient with vision loss taking amantadine, possible comorbid ocular pathologies should be ruled out by extensive slit lamp examination of the anterior segment, retina, and optic nerve. Slit-lamp examination of the cornea shows diffuse stromal edema with Descemet's folds and absent guttae. Microcystic epithelial edema and loosened epithelia have also been described.</p>
      </sec>
      <sec id="article-100318.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Further studies, such as pachymetry, can be used to confirm the presence of corneal edema, monitor disease progression and resolution with discontinuation of amantadine. Specular microscopy studies can be performed to assess the extent of endothelial damage and ECD.</p>
      </sec>
      <sec id="article-100318.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The majority of reported cases of amantadine keratopathy have shown complete resolution of corneal edema and visual acuity with discontinuation of amantadine.<xref ref-type="bibr" rid="article-100318.r2">[2]</xref><xref ref-type="bibr" rid="article-100318.r3">[3]</xref><xref ref-type="bibr" rid="article-100318.r4">[4]</xref><xref ref-type="bibr" rid="article-100318.r11">[11]</xref>&#x000a0;There have been a few reported cases where corneal edema did not resolve after discontinuation of amantadine.<xref ref-type="bibr" rid="article-100318.r7">[7]</xref><xref ref-type="bibr" rid="article-100318.r12">[12]</xref>&#x000a0;In these cases, visual acuity returned to normal following corneal transplant surgery. It is also possible that comorbid corneal pathologies may have caused further damage to the cornea, preventing the resolution of the disease even with discontinuation of therapy.<xref ref-type="bibr" rid="article-100318.r16">[16]</xref>&#x000a0;A more recent case report showed that a patient with a history of amantadine keratopathy was able to continue using the drug with topical steroids without recurrence of edema or a decrease in endothelial cell density.<xref ref-type="bibr" rid="article-100318.r17">[17]</xref>&#x000a0;Although topical steroids have not been shown to decrease corneal edema, they could be useful as a prophylactic measure in susceptible individuals.</p>
        <p>Currently, there is little to no evidence to stratify a patient&#x02019;s risk of developing amantadine keratopathy. Decreased vision following initiation of treatment should undoubtedly prompt a referral to an ophthalmologist by the prescribing neurologist. Patients with a history of ocular trauma, ocular surgery, corneal or anterior segment disease, and possibly those of a certain age may necessitate a consultation by a corneal specialist prior to initiation of amantadine therapy. However, further research is needed to elucidate guidelines for such practice. Increased corneal backscatter on slit-lamp examination and CCT have been shown to have weak predictive value in the prognosis of FECD.<xref ref-type="bibr" rid="article-100318.r18">[18]</xref><xref ref-type="bibr" rid="article-100318.r19">[19]</xref>&#x000a0;It is unlikely that these data points would be helpful for ophthalmologists in evaluating patients before initiating amantadine therapy. Newer forms of analysis of the cornea, including Scheimpflug tomography, show significant promise in predicting the need for future interventions in FECD prior to the loss of visual acuity.<xref ref-type="bibr" rid="article-100318.r18">[18]</xref>&#x000a0;Scheimpflug tomography could be an effective screening method for amantadine keratopathy, although no research has been conducted on this topic.</p>
      </sec>
      <sec id="article-100318.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Fuchs endothelial dystrophy (FECD): Fuchs endothelial dystrophy has the most similar pathophysiology and presentation to amantadine keratopathy. Differentiating features include the presence of guttata on slit-lamp examination and persistence following discontinuation of amantadine.</p>
        <p>Band keratopathy: Calcium deposition in the anterior stroma can look similar to the stomal edema associated with amantadine keratopathy, and the epidemiology is similar due to the age-related progression and association with chronic disease. Patients will generally have a sub-acute or chronic progression of corneal opacification as opposed to that in amantadine keratopathy, and there is an increased association with ocular comorbidities. Like FECD, band keratopathy will not resolve with discontinuation of amantadine.</p>
      </sec>
      <sec id="article-100318.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The majority of reported cases have shown a complete resolution of corneal edema and return of visual acuity to baseline upon discontinuation of amantadine, especially in those with no prior ocular history. In patients with an already decreased endothelial cell density, corneal transplant or Descemet membrane endothelial keratoplasty may be indicated.</p>
      </sec>
      <sec id="article-100318.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Misdiagnosis could lead to unnecessary surgeries and medical interventions as well as significant distress for patients who fail to improve. Because amantadine keratopathy causes permanent damage to the corneal endothelium, failure to recognize this disease or individuals who are susceptible could lead to permanent loss of vision.</p>
      </sec>
      <sec id="article-100318.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Amantadine keratopathy is swelling of the cornea secondary to damage of cells responsible for keeping the cornea deturgescent and transparent. Although the damage is irreversible, the swelling usually resolves with discontinuation of the drug. If symptoms that were previously controlled with amantadine therapy worsen with discontinuation, the neurologist and ophthalmologist need to discuss how to optimize the patient's therapy.</p>
      </sec>
      <sec id="article-100318.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Greater awareness of keratopathy as an adverse effect of amantadine therapy is needed by the interprofessional team that cares for patients with neurodegenerative or neurocognitive disorders. This team includes neurologists, ophthalmologists, and primary care&#x000a0;clinicians. Ophthalmologists should understand the pathophysiology of amantadine keratopathy and the irreversible damage to corneal endothelium associated with it. Because medications prescribed by neurodegenerative and neurocognitive disease specialists have an extensive profile of adverse reactions, increased diligence in the review of medications may be necessary for these patients. Nurses and&#x000a0;pharmacists can help in identifying this disease by extensively screening patients' past medical history and medications list. The prevalence, risk factors, and complications of amantadine keratopathy remain largely unknown and serve as a possible topic of future research.</p>
      </sec>
      <sec id="article-100318.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=100318&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=100318">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/eye-health/amantadine-keratopathy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=100318">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/100318/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=100318">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-100318.s15">
        <title>References</title>
        <ref id="article-100318.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Jeong</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Wee</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Jeon</surname>
                <given-names>BS</given-names>
              </name>
            </person-group>
            <article-title>The effect of amantadine on corneal endothelium in subjects with Parkinson's disease.</article-title>
            <source>Ophthalmology</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>117</volume>
            <issue>6</issue>
            <fpage>1214</fpage>
            <page-range>1214-9</page-range>
            <pub-id pub-id-type="pmid">20153901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100318.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Esquenazi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Bilateral reversible corneal edema associated with amantadine use.</article-title>
            <source>J Ocul Pharmacol Ther</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>25</volume>
            <issue>6</issue>
            <fpage>567</fpage>
            <page-range>567-70</page-range>
            <pub-id pub-id-type="pmid">20028266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100318.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kubo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Iwatake</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ebihara</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Murakami</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hattori</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Visual impairment in Parkinson's disease treated with amantadine: case report and review of the literature.</article-title>
            <source>Parkinsonism Relat Disord</source>
            <year>2008</year>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>166</fpage>
            <page-range>166-9</page-range>
            <pub-id pub-id-type="pmid">17509924</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100318.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Teja</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baig</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Bilateral corneal edema associated with amantadine.</article-title>
            <source>CMAJ</source>
            <year>2015</year>
            <month>Oct</month>
            <day>20</day>
            <volume>187</volume>
            <issue>15</issue>
            <fpage>1155</fpage>
            <page-range>1155-1158</page-range>
            <pub-id pub-id-type="pmid">25991839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100318.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daggumilli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vanathi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ganger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tandon</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Corneal Evaluation in Patients With Parkinsonism on Long-Term Amantadine Therapy.</article-title>
            <source>Cornea</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>38</volume>
            <issue>9</issue>
            <fpage>1131</fpage>
            <page-range>1131-1136</page-range>
            <pub-id pub-id-type="pmid">30973404</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100318.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Tu</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Amantadine Use as a Risk Factor for Corneal Edema: A Nationwide Cohort Study in Taiwan.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>171</volume>
            <fpage>122</fpage>
            <page-range>122-129</page-range>
            <pub-id pub-id-type="pmid">27594137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100318.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koenig</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>McDermott</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Simons</surname>
                <given-names>KB</given-names>
              </name>
            </person-group>
            <article-title>Nonimmunologic graft failure after Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK) for presumed amantadine-induced corneal edema.</article-title>
            <source>Eye Contact Lens</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>209</fpage>
            <page-range>209-11</page-range>
            <pub-id pub-id-type="pmid">19516146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100318.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abib</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Barreto Junior</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Behavior of corneal endothelial density over a lifetime.</article-title>
            <source>J Cataract Refract Surg</source>
            <year>2001</year>
            <month>Oct</month>
            <volume>27</volume>
            <issue>10</issue>
            <fpage>1574</fpage>
            <page-range>1574-8</page-range>
            <pub-id pub-id-type="pmid">11687354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100318.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kwon</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Gore</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>McCartney</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Chuck</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Analyses of Factors Affecting Endothelial Cell Density in an Eye Bank Corneal Donor Database.</article-title>
            <source>Cornea</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>35</volume>
            <issue>9</issue>
            <fpage>1206</fpage>
            <page-range>1206-10</page-range>
            <pub-id pub-id-type="pmid">27310882</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100318.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>French</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Margo</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Postmarketing surveillance of corneal edema, Fuchs dystrophy, and amantadine use in the Veterans Health Administration.</article-title>
            <source>Cornea</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>26</volume>
            <issue>9</issue>
            <fpage>1087</fpage>
            <page-range>1087-9</page-range>
            <pub-id pub-id-type="pmid">17893540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100318.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Wee</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Corneal endothelial dysfunction associated with amantadine toxicity.</article-title>
            <source>Cornea</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>27</volume>
            <issue>10</issue>
            <fpage>1182</fpage>
            <page-range>1182-5</page-range>
            <pub-id pub-id-type="pmid">19034138</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100318.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeng</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Galor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Meisler</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Hollyfield</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Schoenfield</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>McMahon</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Langston</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Amantadine-associated corneal edema potentially irreversible even after cessation of the medication.</article-title>
            <source>Ophthalmology</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>115</volume>
            <issue>9</issue>
            <fpage>1540</fpage>
            <page-range>1540-4</page-range>
            <pub-id pub-id-type="pmid">18501429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100318.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonz&#x000e1;lez Della Valle</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ruzo</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Salvati</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Warfarin-associated intracapsular hemorrhage causing an acutely painful total hip arthroplasty: a rare complication of prolonged anticoagulant therapy.</article-title>
            <source>J Arthroplasty</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>668</fpage>
            <page-range>668-70</page-range>
            <pub-id pub-id-type="pmid">10960007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100318.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feng</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>McKee</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>MO</given-names>
              </name>
            </person-group>
            <article-title>Memantine-associated corneal endothelial dysfunction.</article-title>
            <source>JAMA Ophthalmol</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>133</volume>
            <issue>10</issue>
            <fpage>1218</fpage>
            <page-range>1218-20</page-range>
            <pub-id pub-id-type="pmid">26248040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100318.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mancera</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wadia</surname>
                <given-names>HP</given-names>
              </name>
            </person-group>
            <article-title>Corneal Edema Associated With Systemic Dopaminergic Agents.</article-title>
            <source>Cornea</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>38</volume>
            <issue>8</issue>
            <fpage>1040</fpage>
            <page-range>1040-1042</page-range>
            <pub-id pub-id-type="pmid">30950895</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100318.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naumann</surname>
                <given-names>GO</given-names>
              </name>
              <name>
                <surname>Schl&#x000f6;tzer-Schrehardt</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Amantadine-associated corneal edema.</article-title>
            <source>Ophthalmology</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>116</volume>
            <issue>6</issue>
            <fpage>1230</fpage>
            <page-range>1230-1; author reply 1231</page-range>
            <pub-id pub-id-type="pmid">19486806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100318.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hessen</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Vahedi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khoo</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Vakili</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Eghrari</surname>
                <given-names>AO</given-names>
              </name>
            </person-group>
            <article-title>Clinical and genetic investigation of amantadine-associated corneal edema.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2018</year>
            <volume>12</volume>
            <fpage>1367</fpage>
            <page-range>1367-1371</page-range>
            <pub-id pub-id-type="pmid">30122888</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100318.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Hodge</surname>
                <given-names>DO</given-names>
              </name>
              <name>
                <surname>Treichel</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Spiegel</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Baratz</surname>
                <given-names>KH</given-names>
              </name>
            </person-group>
            <article-title>Predicting the Prognosis of Fuchs Endothelial Corneal Dystrophy by Using Scheimpflug Tomography.</article-title>
            <source>Ophthalmology</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>127</volume>
            <issue>3</issue>
            <fpage>315</fpage>
            <page-range>315-323</page-range>
            <pub-id pub-id-type="pmid">31685256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100318.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Cleynenbreugel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Remeijer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hillenaar</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Cataract surgery in patients with Fuchs' endothelial corneal dystrophy: when to consider a triple procedure.</article-title>
            <source>Ophthalmology</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>121</volume>
            <issue>2</issue>
            <fpage>445</fpage>
            <page-range>445-53</page-range>
            <pub-id pub-id-type="pmid">24289914</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
